Mosaic ImmunoEngineering (CPMV) just unveiled an announcement.
Mosaic ImmunoEngineering, Inc. has agreed to a deal with Oncotelic Therapeutics, Inc. to acquire rights to cutting-edge necroptosis cancer therapies and AI technologies for immunotherapy combinations. Mosaic will compensate Oncotelic with up to $30 million in stock, subject to the achievement of certain milestones and additional funding arrangements. The deal may evolve into a reverse acquisition if Mosaic cannot secure the necessary funds, with both parties committed to finalizing the definitive agreements following due diligence.
See more data about CPMV stock on TipRanks’ Stock Analysis page.
